摘要目的 观察重组干扰素α-2b对病毒性角膜炎的临床疗效.方法 476例(489只眼)患者除常规使用高滴度局部抗病毒药物,同时使用重组干扰素α-2b 100万u皮下注射,隔日1次,评价其临床安全性和有效性.结果 患者的总体治愈率为59.1%,由高到低依次为基质型、内皮型、上皮型、全角膜型;总体复发率为23.5%,由高到低依次为上皮型、全角膜型、内皮型、基质型.药物的不良反应发生率为10.7%.结论 重组干扰素α-2b能提高病毒性角膜炎的治愈率,降低复发率;100万u的重组干扰素α-2b在眼科临床上应用具有较高的安全性.

abstractsObjective To observe the clinical effect of interferon on the treatment of virus keratitis. Meth-ods Review and analysis was made of 476 patients with virus keratitis who was treated with high concentration of an-ti-virus eyedrops and one million unit of α-2b interferon, the clinical safety and effect was evaluated. Result The total cure rate was 59. 1%, and the type from high to low is interstitial、endothelial、epithelial and the total cornea. The total recurrence rate is 23.5% ,and the type from high to low is epithelial,the total cornea,endothelial and inter-stitial. The incidence rate of the adverse effect is 10. 7%. Condusion Systemic administration of interferon has a direct anti-virus effect, and it can raise the cure rate of virus keratitis as well as decrease recurrencerate. One million unit of interferon has a high clinical safety and effect.